Ocular Drug Delivery Market to Grow at a CAGR of 7.4% to reach US$ 27,016.20 million from 2021 to 2028

report image

Ocular Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems, Nano-Particle Drug Delivery System, and Others), Formulation Type (Liposomes and Nanoparticles, Solution, Emulsion, Suspension, and Ointment), Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, and Others), and End User (Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers) and Geography

Publication Month: Sep 2021 | Report Code: TIPRE00004206 | No. of Pages: 171 | Category: Pharmaceuticals | Status: Published

The ocular drug delivery market was valued at US$ 16,404.32 million in 2021 and is projected to reach US$ 27,016.20 million by 2028; it is expected to grow at a CAGR of 7.4 % from 2021 to 2028.  

An ocular drug delivery system (ODDS) is a dosage form, vehicle, or system intended to instill, administer, or deliver drug/medicine to the eye against any ailment or disorder involving or affecting vision. It ranges from simple sterile eye drop for the ocular surface to complex implants for intraocular tissue. Ocular drug formulations are primarily liquid forms, such as solutions, suspensions, and emulsions for treating anterior eye segment diseases. These formulations can be available in the form of advanced drug delivery systems like in-situ gel, microemulsion, nanoparticle, liposome, iontophoresis, nanosuspension, and ocular inserts.     

Strategic Insights

Report Coverage - Ocular Drug Delivery Market
Report CoverageDetails
Market Size Value inUS$ 16,404.32 million in 2021
Market Size Value byUS$ 27,016.20 million by 2028
Growth rateCAGR of 7.4% from 2021-2028
Forecast Period2021-2028
Base Year2021
No. of Pages171
No. of Tables56
No. of Charts & Figures20
Historical data availableYes
Segments coveredTechnology, Formulation Type, Disease Type, End User and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available
                       

The ocular drug delivery market has been segmented based on technology, formulation type, disease type, end user, and geography. By geography, the market is primarily segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the ocular drug delivery market, emphasizing parameters such as market trends, technological advancements, and market dynamics, along with competitive landscape analysis of the globally leading market players.  

Lucrative Regions for Ocular drug delivery Market

Lucrative Regions for Ocular drug delivery Market

Get more information on this report :

Market Insights


Growing Prevalence of Eye Disorders to Boost Ocular Drug Delivery Market Growth

The leading cause of blindness or low vision across the globe is cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, and unaddressed refractive error. The majority of the global population have or had some eye disorder in their lifetime. As per the World Health Organization (WHO) report “Blindness and vision impairment” published in February 2021, around 2.2 billion people worldwide have a near or distance vision impairment. It has also estimated that the leading cause of vision loss or low vision is cataract (94 million) and uncorrected refractive errors (88.4 million). Further, the other common causes of vision loss are glaucoma (7.7 million), corneal opacities (4.2 million), diabetic retinopathy (3.9 million), and trachoma (2 million).

According to the National Eye Institute (NEI), in the US, the number of people with cataracts is expected to double from 24.4 million in 2010 to about 50 million in 2050. Similarly, as per the Factsheet Glaucoma: Facts & Figures 2019, over 3 million people in the US were living with glaucoma.  Moreover, as per the Canadian Survey on Disabilities 2017, 1.5 million Canadians had a sight loss, and around 5.59 million had an eye disease which could further lead to sight loss.

Additionally, as per the Royal National Institute of Blind People in 2017, in the UK, there were around 350,000 people registered as blind and partially sighted; about 173,735 were registered for severely sight impaired; and 176,125 were registered for sight-impaired.  

Technology-Based Insights                               

Based on technology, the ocular drug delivery market is segmented into implantable ocular drug delivery systems, particulate drug delivery systems, nano-particle drug delivery system, and others. The implantable ocular drug delivery systems segment would account for the largest market share in 2021, and the same segment is anticipated to register the highest CAGR during the forecast period.

Ocular drug delivery Market, by Technology – 2021 and 2028

Ocular drug delivery Market, by Technology – 2021 and 2028

Get more information on this report :

Formulation Type-Based Insights                       

Based on formulation type, the ocular drug delivery market is segmented into liposomes and nanoparticles, solution, emulsion, suspension, and ointment. The solution segment would hold the largest share of the market in 2021, and it is estimated to register the highest CAGR in the market during 2021–2028. The growth of the solution segment is attributed to the increasing adoption of ocular drug delivery systems in solution forms, like eye drops and injectables.

Disease Type–Based Insights

Based on disease type, the ocular drug delivery market is segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. The cataract segment would account for the largest market share in 2021. The market for this segment is estimated to grow at the highest CAGR from 2021 to 2028.

End User–Based Insights

Based on end user, the ocular drug delivery market is segmented into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment would hold the largest share of the market in 2021, while the ophthalmic clinics segment is estimated to register the highest CAGR in the market during the forecast period. 

The COVID-19 pandemic has become the most significant challenge across the world. As this pandemic has stressed healthcare systems across the globe, prioritizing the limited resources was essential to minimize hospital admissions. However, despite increased demand for ocular therapeutics such as eye drops, ointment, and suspension, there was a shortage of these products as new consumers entered the market. Manufacturers are also experiencing raised prices and potential shortages of raw ingredients due to supply restrictions. However, as the restrictions have been lifted and businesses are resuming, the demand-supply variables are coming back to normal. This will offer several growth prospects for ocular drug delivery therapeutics.   

Acquisitions, collaborations, partnerships, product launches, and expansions are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The ocular drug delivery market players have been chiefly adopting the strategy of product innovation to cater to the changing customer demand across the world, which also helps them maintain their brand name globally.

Company Profiles

  • AbbVie Inc.                                         
  • Bausch Health Companies Inc.                
  • Taiwan Liposome Company, Ltd.             
  • Ocular Therapeutix, Inc.                        
  • GRAYBUG VISION, INC.                         
  • Alimera Sciences, Inc.                          
  • Envisia Therapeutics                             
  • Novartis AG                                        
  • EYEGATE PHARMACEUTICALS, INC           
  • Clearside Biomedical, Inc.

Frequently Asked Questions

Ocular drug delivery system (ODDS) is a dosage form, vehicle, or system intended for instilling, administering, or delivering drug/medicine to eye against any ailment or disorder involving or affecting vision. It ranges from simple sterile eye drop for the ocular surface to complex implants for intraocular tissue. Ocular drugs formulations are primarily available in liquid form such as solutions, suspensions, and emulsions for treating anterior eye segment diseases. These formulations can be available in the form of advanced drug delivery systems like in-situ gel, microemulsion, nanoparticle, liposome, iontophoresis, nanosuspension, and ocular inserts.
The factors that are driving growth of the market are growing prevalence of eye disorders and rising research on ocular drug delivery.
The factors that are restraining the adoption of ocular drug delivery are several disadvantages associated with ocular drug delivery.
The Ocular drug delivery market majorly consists of the players such as players AbbVie Inc., Bausch Health Companies Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision, Inc., Alimera Sciences, Inc., Envisia Therapeutics, Novartis AG, EyeGate Pharmaceuticals, Inc, Clearside Biomedical, Inc. and among others.

The List of Companies - Ocular Drug Delivery Market

  1. AbbVie Inc.          
  2. Bausch Health Companies Inc.      
  3. Taiwan Liposome Company, Ltd.              
  4. Ocular Therapeutix, Inc.    
  5. GRAYBUG VISION, INC.               
  6. Alimera Sciences, Inc.      
  7. Envisia Therapeutics         
  8. Novartis AG         
  9. EYEGATE PHARMACEUTICALS, INC        
  10. Clearside Biomedical, Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Ocular drug delivery market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Ocular drug delivery market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00004206
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount